Potent anaplastic lymphoma kinase (ALK) inhibitor (IC50
= 3.5 nM). Also inhibits Ack and ROS1 activity (IC50
values are 5.8 and 8.9 nM respectively). Attenuates proliferation, and induces apoptosis of NPM-ALK+
T cell anaplastic large-cell lymphoma (ALCL) cells in vitro
. Suppresses tumor growth of NPM-ALK+
ALCL cell xenografts in mice. Causes tumor shrinkage in hEML4-ALK transgenic mice. Orally available.
Soluble to 20 mM in DMSO
Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
George et al.
ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond.
Awad and Shaw
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori et al.
Mol.Cancer Ther., 2014;13:329